Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
27 08 2022
Historique:
received: 25 04 2022
accepted: 15 08 2022
revised: 11 08 2022
entrez: 27 8 2022
pubmed: 28 8 2022
medline: 31 8 2022
Statut: epublish

Résumé

In addition to an inflammatory reaction, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected patients present lymphopenia, which we recently reported as being related to abnormal programmed cell death. As an efficient humoral response requires CD4 T-cell help, we hypothesized that the propensity of CD4 T cells to die may impact the quantity and quality of the humoral response in acutely infected individuals. In addition to specific immunoglobulins (Ig)A, IgM, and IgG against SARS-CoV-2 nucleocapsid (N), membrane (M), and spike (S1) proteins, we assessed the quality of IgG response by measuring the avidity index. Because the S protein represents the main target for neutralization and antibody-dependent cellular cytotoxicity responses, we also analyzed anti-S-specific IgG using S-transfected cells (S-Flow). Our results demonstrated that most COVID-19 patients have a predominant IgA anti-N humoral response during the early phase of infection. This specific humoral response preceded the anti-S1 in time and magnitude. The avidity index of anti-S1 IgG was low in acutely infected individuals compared to convalescent patients. We showed that the percentage of apoptotic CD4 T cells is inversely correlated with the levels of specific IgG antibodies. These lower levels were also correlated positively with plasma levels of CXCL10, a marker of disease severity, and soluble Fas ligand that contributes to T-cell death. Finally, we found lower S-Flow responses in patients with higher CD4 T-cell apoptosis. Altogether, these results demonstrate that individuals with high levels of CD4 T-cell apoptosis and CXCL10 have a poor ability to build an efficient anti-S response. Consequently, preventing CD4 T-cell death might be a strategy for improving humoral response during the acute phase, thereby reducing COVID-19 pathogenicity.

Identifiants

pubmed: 36030261
doi: 10.1038/s41419-022-05190-0
pii: 10.1038/s41419-022-05190-0
pmc: PMC9419645
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

741

Informations de copyright

© 2022. The Author(s).

Références

Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
J Immunol. 1999 Mar 15;162(6):3549-58
pubmed: 10092813
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Lancet. 1988 Nov 12;2(8620):1104-7
pubmed: 2903324
Immunol Rev. 1997 Apr;156:53-66
pubmed: 9176699
J Exp Med. 1993 Jun 1;177(6):1809-14
pubmed: 8496693
Clin Vaccine Immunol. 2015 Dec 09;23(3):243-5
pubmed: 26656116
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
J Immunol. 2014 Dec 1;193(11):5370-8
pubmed: 25411432
J Clin Virol. 2020 Dec;133:104655
pubmed: 33069846
Cell. 1993 Dec 17;75(6):1169-78
pubmed: 7505205
Cell. 2020 Dec 10;183(6):1496-1507.e16
pubmed: 33171099
Immunity. 1998 Nov;9(5):711-20
pubmed: 9846492
Nat Cell Biol. 2021 Dec;23(12):1314-1328
pubmed: 34876692
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
J Infect Dis. 2021 Sep 1;224(5):764-770
pubmed: 34086960
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444980
PLoS One. 2017 Jan 3;12(1):e0169100
pubmed: 28046003
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
FASEB J. 1994 Aug;8(11):832-40
pubmed: 8070632
J Immunol. 1999 Jul 15;163(2):583-9
pubmed: 10395644
J Immunol. 2007 Nov 1;179(9):6237-45
pubmed: 17947699
Cell Death Differ. 2022 Jun;29(6):1107-1122
pubmed: 35581387
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33529167
Nature. 1995 Feb 2;373(6513):441-4
pubmed: 7530336
Am J Pathol. 2000 Jun;156(6):1951-9
pubmed: 10854218
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Med. 2021 Jul;27(7):1178-1186
pubmed: 33953384
Am J Respir Cell Mol Biol. 1998 Oct;19(4):537-42
pubmed: 9761749
Cell. 2020 Dec 10;183(6):1508-1519.e12
pubmed: 33207184
J Exp Med. 1992 Jun 1;175(6):1539-46
pubmed: 1588279
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Lancet. 2004 Feb 21;363(9409):617-9
pubmed: 14987888
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
J Clin Immunol. 2011 Jun;31(3):430-5
pubmed: 21318330
J Infect Dis. 1990 Jul;162(1):270-3
pubmed: 2192008
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
J Exp Med. 1989 Sep 1;170(3):1039-44
pubmed: 2788703
Nature. 2021 Jul;595(7865):114-119
pubmed: 33915568
FASEB J. 2004 Jan;18(1):191-3
pubmed: 14597565
J Biol Chem. 2008 Feb 8;283(6):3272-3280
pubmed: 18055455
PLoS Pathog. 2015 Dec 07;11(12):e1005287
pubmed: 26640894
Cell Death Differ. 2021 Sep;28(9):2765-2777
pubmed: 33879858
Nat Med. 1999 Apr;5(4):423-6
pubmed: 10202932
Immunol Rev. 2019 Mar;288(1):85-96
pubmed: 30874350
Cell Rep Med. 2021 Mar 16;2(3):100208
pubmed: 33564749
J Appl Lab Med. 2020 Sep 1;5(5):908-920
pubmed: 32428207
Nat Immunol. 2021 Apr;22(4):404-411
pubmed: 33723418
Microorganisms. 2020 Nov 28;8(12):
pubmed: 33260775
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
Nat Biomed Eng. 2020 Dec;4(12):1188-1196
pubmed: 33122853
Heliyon. 2021 Apr;7(4):e06836
pubmed: 33898857
Sci Transl Med. 2015 Jul 29;7(298):298ra120
pubmed: 26223303
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Nat Microbiol. 2021 Jan;6(1):51-58
pubmed: 33199863
Clin Diagn Lab Immunol. 1999 Sep;6(5):725-8
pubmed: 10473525
Sci Transl Med. 2020 Sep 2;12(559):
pubmed: 32817357
J Exp Med. 1987 Oct 1;166(4):1084-97
pubmed: 2443596
Cell Death Differ. 2022 Aug;29(8):1486-1499
pubmed: 35066575
Immunol Rev. 2005 Aug;206:32-63
pubmed: 16048541
J Exp Med. 1996 Sep 1;184(3):963-9
pubmed: 9064356
Microbios. 1996;87(351):113-21
pubmed: 9032960
J Clin Invest. 2020 Dec 1;130(12):6477-6489
pubmed: 32833687
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 32958614
Emerg Infect Dis. 2020 Oct;26(10):2484-2487
pubmed: 32579877
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Front Immunol. 2017 Feb 20;8:135
pubmed: 28265271
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
J Infect Dis. 2020 Sep 14;222(8):1265-1269
pubmed: 32726417
J Immunol. 1997 Oct 15;159(8):3961-7
pubmed: 9378984

Auteurs

Sonia André (S)

Université Paris Cité, INSERM U1124, F-75006, Paris, France.

Marne Azarias da Silva (M)

Université Paris Cité, INSERM U1124, F-75006, Paris, France.

Morgane Picard (M)

Université Paris Cité, INSERM U1124, F-75006, Paris, France.

Aurélie Alleaume-Buteau (A)

Université Paris Cité, INSERM U1124, F-75006, Paris, France.
Structural and Molecular Analysis Platform, BioMedTech Facilities INSERM US36-CNRS UMS2009, Université Paris Cité, Paris, France.

Lucy Kundura (L)

Laboratoire d'Immunologie, CHU de Nîmes, Nîmes, France.

Renaud Cezar (R)

Laboratoire d'Immunologie, CHU de Nîmes, Nîmes, France.

Calaiselvy Soudaramourty (C)

Université Paris Cité, INSERM U1124, F-75006, Paris, France.

Santa Cruz André (SC)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Department of Internal Medicine, Hospital of Braga, Braga, Portugal.
Clinical Academic Center-Braga, Braga, Portugal.

Ana Mendes-Frias (A)

Department of Internal Medicine, Hospital of Braga, Braga, Portugal.
Clinical Academic Center-Braga, Braga, Portugal.

Alexandre Carvalho (A)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Department of Internal Medicine, Hospital of Braga, Braga, Portugal.
Clinical Academic Center-Braga, Braga, Portugal.

Carlos Capela (C)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Department of Internal Medicine, Hospital of Braga, Braga, Portugal.
Clinical Academic Center-Braga, Braga, Portugal.

Jorge Pedrosa (J)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.

António Gil Castro (A)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Paul Loubet (P)

Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France.

Albert Sotto (A)

Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France.

Laurent Muller (L)

Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.

Jean-Yves Lefrant (JY)

Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.

Claire Roger (C)

Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.

Pierre-Géraud Claret (PG)

Urgences Médico-Chirugicales Hospitalisation, CHU de Nîmes, Nîmes, France.

Sandra Duvnjak (S)

Service de Gérontologie et Prévention du Vieillissement, CHU de Nîmes, Nîmes, France.

Tu-Anh Tran (TA)

Service de Pédiatrie, CHU de Nîmes, Nîmes, France.

Ouafa Zghidi-Abouzid (O)

CHU de Québec-Université Laval Research Center, Québec City, QC, Canada.

Pierre Nioche (P)

Université Paris Cité, INSERM U1124, F-75006, Paris, France.
Structural and Molecular Analysis Platform, BioMedTech Facilities INSERM US36-CNRS UMS2009, Université Paris Cité, Paris, France.

Ricardo Silvestre (R)

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Pierre Corbeau (P)

Laboratoire d'Immunologie, CHU de Nîmes, Nîmes, France. pierre.corbeau@igh.cnrs.fr.
Institut de Génétique Humaine UMR9002 CNRS-Université de Montpellier, Montpellier, France. pierre.corbeau@igh.cnrs.fr.

Fabrizio Mammano (F)

Université Paris Cité, INSERM U1124, F-75006, Paris, France. fabrizio.mammano@inserm.fr.
INSERM U1259 MAVIVH, Université de Tours, Tours, France. fabrizio.mammano@inserm.fr.

Jérôme Estaquier (J)

Université Paris Cité, INSERM U1124, F-75006, Paris, France. estaquier@yahoo.fr.
CHU de Québec-Université Laval Research Center, Québec City, QC, Canada. estaquier@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH